Henry R. Wolfe

Biography

  Dr. Wolfe joined Antares Pharma in January 2017 as Senior Vice President of Pharmaceutical Development with more than 30 years of experience in the pharmaceutical and biotechnology industry. Immediately prior to joining Antares, Dr. Wolfe was Vice President of Biologics at Sun Pharma where he was responsible for the development of an NCE monoclonal antibody (tildrakizumab) in both prefilled syringe and auto-injector forms. In an earlier role at Sun, Dr. Wolfe was Vice President of Generics R&D with roles in both pharmaceutical and clinical development. Prior to its acquisition by Sun, Dr. Wolfe was Vice President of Generics R&D at URL Pharma with responsibilities for pharmaceutical development, pharmacology/toxicology and 505b2 programs. Additionally, Dr. Wolfe was the Chief Scientific Officer at two biotechnology companies (CombiMab and Genaera) focused on the development of parenteral small molecules, peptide and protein NCEs. Dr. Wolfe received a BA degree in Biology from Towson University, an MS in Biochemistry and Nutrition from Virginia Polytechnic Institute and a PhD in Molecular Pharmacology and Structural Biology from Thomas Jefferson University. 

Research Interest